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Abstract Fermentation of glucose to lactate in the presence
of sufficient oxygen, known as aerobic glycolysis or
Warburg effect, is a universal phenotype of cancer cells.
Understanding its origin and role in cellular immortaliza-
tion and transformation has attracted considerable attention
in the recent past. Intriguingly, while we now know that
Warburg effect is essential for tumor growth and develop-
ment, it is thought to arise because of genetic and/or
epigenetic changes. In contrast to the above, we propose
that Warburg effect can also arise due to normal biochem-
ical fluctuations, independent of genetic and epigenetic
changes. Cells that have acquired Warburg effect proliferate
rapidly to give rise to a population of heterogeneous
progenitors of cancer cells. Such cells also generate more
lactate and alter the fitness landscape. This dynamic fitness
landscape facilitates evolution of cancer cells from its
progenitors, in a fashion analogous to Darwinian evolution.
Thus, sporadic cancer can also occur first by the acquisition
of Warburg effect, then followed by mutation and selection.
The idea proposed here circumvents the inherent difficulties
associated with the current understanding of tumorigenesis,
and is also consistent with many experimental and
epidemiological observations. We discuss this model in
the context of epigenetics as originally enunciated by
Waddington.
Keywords Cancer epigenetics .Warburg effect . Crabtree
effect . Cellular heterogeneity . Biological noise . Aerobic
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Introduction
Current understanding of tumorigenesis is based on
experimental, epidemiological, and evolutionary thoughts
developed over the past few decades. Tumorigenesis
appears to be due to random genetic and/or epigenetic
alterations, and is thought to be a unidirectional process
which occurs in a stepwise manner analogous to Darwinian
evolution (Gatenby and Vincent 2003; Merlo et al. 2006).
That is, normal cells acquire cancer phenotype because of
mutations that bestow on them the fitness advantage to
adapt to the constantly changing environmental and/or
cellular constraints. Tumor cells are thought to originate
from a common ancestor and are therefore functionally
equivalent (Armitage and Doll 1954; Nowell 1976). The
above model, commonly referred to as somatic mutation
theory, was further supported with the identification of a
large array of dominantly acting oncogenes and recessively
acting tumor suppressor genes (Hahn and Weinberg 2002).
As opposed to the “common ancestor” concept of somatic
mutation theory, the cancer stem cell concept states that a
subpopulation of cells of a tumor, referred to as cancer stem
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cells, derived from normal stem cells, or from differentiated
cells due to random genetic/epigenetic events, gives rise to
cancer cells incessantly (Reya et al. 2001; Bjerkvig et al.
2005; Feinberg et al. 2006; Dick 2008; Grønbaek et al.
2007). Although somatic mutation theory and cancer stem
cell theory have been in vogue, many fundamental issues
still remain unresolved (Soto and Sonnenschein 2004).
Alternate possibilities that circumvent the inherent incon-
sistencies associated with the above models but do not
strictly depend upon random genetic or epigenetic changes
for initiating tumorigenesis has also been articulated
(Kauffman 1971; Potter 2001; Laforge et al. 2005; Huang
and Ingber 2007; Brock et al. 2009).
However, a close examination of the various models
reveals that a unified concept of origin of cancer has not yet
emerged, despite intense efforts to integrate a wealth of
disparate data accumulated over the past several decades.
Notwithstanding the presence of a bewildering array of
genetic and epigenetic lesions, recent studies clearly point
out that Warburg effect (conversion of glucose to lactate in
the presence of oxygen), an essential feature of tumor cells,
is thought to be a consequence of genetic or epigenetic
alterations (Dang and Semenza 1999; Gatenby and Gillies
2004; Shaw 2006; Vander and Cantley 2009; Hsu and
Sabatini 2008; Kaelin and Thompson 2010; Kroemer and
Pouyssegur 2008). However, the intricate relationship that
is observed between aerobic glycolysis and genetic alter-
ations in cancer cells clearly points out that there exists a
missing link between these two phenomena. Here, we
propose that Warburg effect can also be a cause of cancer,
and seek to unearth the “missing link” to explore its
implications in the context of what we already know about
cancer.
Warburg effect: fact or an artifact?
That Warburg effect occurs constitutively in cancer cells
was first observed by Otto Warburg in the 1920s. This
phenomenon was hypothesized to be due to an impairment
in mitochondrial function (Warburg 1956). Because of the
lack of experimental support, this idea was summarily
abandoned (Weinhouse 1977). Initially, it was thought that
the Warburg effect is an adaptation to hypoxic conditions,
but later studies showed that mutations that lead to
tumorigenesis also cause aerobic glycolysis by upregulating
the expression of glycolytic genes at the transcriptional
level (Semenza 2003). Warburg effect was initially thought
to be incompatible with the concept of stepwise evolution-
ary progression of normal cells to cancer cells. This is
because Warburg effect is an inefficient energy generating
process, and also causes an acidic environment not suitable
for cell proliferation by producing lactate. Therefore, it was
assumed that it cannot confer rapid proliferation and
provide selective advantage to cancer cells. However, it is
now widely accepted that, in fact, Warburg effect is one of
the key features of tumorigenesis, and not only promotes
rapid uncontrolled proliferation but also confers invasive
property (Gatenby and Gillies 2004). In fact, solid tumors
often exhibit areas of hypoxia and acidosis (Fang et al.
2008). Analysis based on evolutionary game theory and
systems biology also points out the importance of Warburg
effect in tumorigenesis (Basanta et al. 2008; Vazquez et al.
2010). Thus, we have come a long way in realizing that
cancer cells cannot do away with aerobic glycolysis.
Molecular basis of the Warburg effect: metabolism
versus mutation
Hypoxia-inducible factor (HIF1) was originally identified
as a DNA-binding transcriptional factor which is present in
nuclear extracts obtained from cells exposed to hypoxic
conditions (Semenza and Wang 1992). It has been
demonstrated that HIF1 activates the transcription of genes,
required for the preferential diversion of glucose to lactate
(see Fig. 1) and is a key factor in tumorigenesis (Kim et al.
2006; Semenza 2007; Baldewijns et al. 2010).
HIF1 is a heterodimer consisting of α and β subunits
(Wang and Semenza 1995). While HIF1β subunit is
constitutively produced, the level of HIF1α is determined
by the rate of its degradation in oxygen (Wang et al. 1995).
Its expression is known to increase exponentially in
hypoxic conditions, but decays rapidly upon oxygenation
with a half-life of 1–5 min, depending upon the experi-
mental condition (Jiang et al. 1996). The degradation of
HIF1α is initiated by the hydroxylation of proline residues
402 and 564, which is required for the subsequent
recognition by von Hippel–Landu tumor suppressor protein
and proteasomal degradation (Jaakkola et al. 2001; Kaelin
2005). α-Ketoglutarate is one of the cosubstrates of the
hydroxylation reactions, and succinate and CO2 are the by-
products (Bruick and McKnight 2001). Succinate and
fumarate inhibit this hydroxylation step, and their increased
levels, due to the mutations in the enzymes required for
their synthesis, correlate with the incidence of cancer (King
et al. 2006; Koivunen, et al. 2007). Recently, it has been
observed that cells defective in either isocitrate dehydro-
genase1 or 2 (ICD1, ICD2) also give rise to cancer
probably because of lower levels of α ketoglutarate
(Parsons et al. 2008; Zhao et al. 2009; Yan et al. 2009;
Murugan et al. 2010). These discoveries point out that a
normal level of α ketoglutarate plays a far more critical
role in suppressing tumorigenesis, emphasizing that the
link between metabolome and genome is far more
complicated than what we originally believed. This
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prompted us to look at the origin of cancer through the
prism of Warburg effect; more specifically, the relationship
between α ketoglutarate and HIF1.
Metabolic basis of the origin of cancer: an alternate
possibility
It is clear from the foregoing section that the activation of
HIF1 above a threshold would increase the flux of glucose
towards lactate with a concomitant decrease towards
oxidative phosphorylation (Fig. 1). Should this happen in
normal cells due to noise, they would acquire aerobic
glycolysis and proliferate rapidly, thus increasing the
likelihood of incorporating genetic or epigenetic changes.
During this process, the fitness landscape also is expected
to change in a dynamic fashion. Under these altered cellular
and environmental conditions, cells that have acquired
fitness advantage due to genetic or epigenetic changes are
likely to succeed. According to this view, the initial event in
sporadic cancer is the fortuitous shift to aerobic glycolysis,
which then provides a unique environment for cells to
proliferate rapidly and evolve in a cooperative fashion. It is
to be noted that many studies have shown that cells with
aerobic glycolysis have a clear proliferative advantage over
cells that use mitochondrial oxidative phosphorylation
(Pfeiffer et al. 2001; Frick and Schuster 2003; Molenaar
et al. 2009).
In the light of Warburg effect, what needs to be
understood is the teleological reason for recruiting of α-
ketoglutarate as a cosubstrate to regulate the activity of
HIF1. We suggest that by recruiting α-ketoglutarate as a
cosubstrate, cell proliferation remains mechanistically cou-
pled to energy production and metabolism. Whenever cells
encounter low levels of α-ketoglutarate because of mito-
chondrial damage (for example, hypoxic conditions), an
HIF1 pathway is automatically activated to increase aerobic
glycolysis. It is pertinent to note here that metazoan
mitochondria are prone to damage because of constant
ROS generation, and accordingly, the mutation rate of
mitochondrial genome is much higher as compared to the
nuclear genome (Wolstenholme and Jeon 1992). In fact,
HIF1 activity suppresses mitochondrial biogenesis and also
aids in mitochondrial autophagy (Zhang et al. 2007, 2008).
Fig. 1 Regulatory features of
the altered fate of glucose me-
tabolism in cancer cells. The
lines with rightwards arrow
indicate activation while lines
with ┤ indicate inhibition; αKG
α ketoglutarate, HIF1 hypoxia-
inducible factor, GLUT1 glucose
transporter. X sign indicates the
loss of function of the relevant
enzymes
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Therefore, activating HIF1 in response to lowered α-
ketoglutarate levels appears to be a part of the normal
homeostatic mechanism. Such a mechanism allows the
organism to proliferate rapidly by fermenting glucose to
lactate, rather than to utilize glucose inefficiently, in case of
a decrease in α ketoglutarate levels, due to intra- and/or
extracellular cues.
Based on the above, we propose that activation of HIF1
ought to be sensitive to varying α-ketoglutarate levels, and
we refer to this attribute as metabolic plasticity. This
metabolic plasticity is a built-in feature that allows even
normal cells to acquire aerobic glycolysis under many
physiological conditions. For example, whenever cells need
to proliferate rapidly, such as in wound healing or
lymphocyte activation, cells switch over to aerobic glycol-
ysis (Wang et al. 1976; Ghani et al. 2004). Recently,
aerobic glycolysis has also been implicated in the estab-
lishment of CD8 T cell memory (Prlic and Bevan 2009).
Thus, metabolic plasticity has evolved to allow cells to
smoothly adapt to constantly varying intra- and extracellu-
lar conditions. That the HIF1 activity could be sensitive to
the changes in α-ketoglutarate levels is reinforced by the
observation that mutation in IDH1 or IDH2, but not both,
are observed in gliomas (Kloosterhof et al. 2010). By
implication, the remaining two ICDs are unable to maintain
the concentration of α-ketoglutarate to a level that is
sufficient to suppress HIF1 activity.
Because α-ketoglutarate is a key intermediate in energy
metabolism as well as in biosynthesis, its concentration is
expected to fluctuate either temporally or at the population
level. If the concentration of α-ketoglutarate decreases to
lower than a threshold which is normally observed, then HIF1
would be fortuitously activated, triggering Warburg effect,
resulting in rapid cell proliferation. By the same token, it is
also possible that this fortuitously acquiredWarburg effect can
wane as a function of time. However, in principle, Warburg
effect, once initiated, can substitute for a mutation (similar to a
recessive or a dominant mutation, as occurs in tumor
suppressor genes or in oncogene activation, respectively),
provided a self-sustaining mechanism stabilizes and prop-
agates it during cell division. Thus, cells that have fortuitously
acquired Warburg effect can serve as progenitors, and would
evolve in Darwinian fashion to become cancer cells. Accord-
ing to this idea, a condition that temporarily impairs oxidative
phosphorylation, (hypoxia, for example), can switch to
aerobic glycolysis, eventually leading to cancer.
Persistence of aerobic glycolysis during cell division:
epigenetic inheritance
A possible mechanism that can stabilize the fortuitously
acquired aerobic glycolysis during cell division is through
feedback loops such as Crabtree effect (aerobic fermentation
with high growth rate, Fig. 1). Crabtree effect is a well-
known phenomenon in yeast (Pronk et al. 1996). It has been
reported that under in vitro conditions, physiological levels
of fructose1, 6-bisphosphate reduces the respiratory flux in
isolated rat liver mitochondria (Díaz-Ruiz et al. 2008),
indicating that Crabtree effect might even operate in humans.
We have developed a theoretical model to demonstrate that
the Crabtree effect, in principle, can sustain aerobic
glycolysis. This model accounts for (1) glycolytic conversion
of glucose to pyruvate and its subsequent conversion to
lactate and α-ketoglutarate; (2) Hydroxylation of HIF 1 by
α-ketoglutarate dependent proline hydroxylase and eventual
degradation of HIF1; (3) the negative and positive feedback
of HIF1 on oxidative phosphorylation and glucose uptake by
the cell, respectively; and (4) the inhibition of TCA cycle
performance through Crabtree effect due to increased flux
through glycolysis. The analysis indicates that the system
shows a bistable response, with two distinct stable states for
various initial concentrations of α-ketoglutarate and HIF1
(Fig. 2). One of the stable states represents active oxidative
phosphorylation with a concentration of α-ketoglutarate that
is present in normal cells (Fig. 3a). As expected, HIF1
activity in these cells is low (Fig. S1, in supplementary
information). The other stable state is characterized by cells
with only 10% of the concentration of α-ketoglutarate, as
observed in normal cells and with a 20-fold higher glucose
uptake rate due to HIF1 activation (Fig. S2, in supplemen-
tary information). Under these conditions, the carbon flux is
mainly routed towards lactate formation (Fig. 3b and details
in Fig. S3, in supplementary information). It is clear from the
analysis that the initial concentration of α-ketoglutarate
dictates the attainment of either of the two states, with
respect to HIF1 activity. Accordingly, when the concentra-
tion of α-ketoglutarate falls below a certain threshold (28%
of the concentration observed in the normal cells, Fig. S1),
the cells reside in the steady state characterized by higher
glucose uptake rates, with the carbon flux shifting towards
lactate formation.
The model was also utilized to determine the percentage
of cells that would reside in the second phenotypic state by
assuming a cell distribution with respect to the concentra-
tion of α-ketoglutarate (see Fig. S4, in supplementary
information). It was quantified by the standard deviation
around the mean, characterizing the concentration of α-
ketoglutarate in a normal cell. The percentage of cells
representing the phenotypic state of oxidative glycolysis
increased exponentially with the standard deviation in the
distribution, indicating a higher propensity for a shift from
the normal behavior (Fig. S5, in the supplementary
information). This analysis indicates that fluctuating levels
of α-ketoglutarate can drive a cell to a new phenotype
purely due to noise in the system.
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If a condition like hypoxia can shift the balance towards
aerobic growth and eventually lead to cancer, one would
expect the incidence of cancer cases to be far more than
what is normally observed. However, it is important to keep
in mind that the level of α-ketoglutarate would be much
more tightly regulated than what we have demonstrated in
the model. Nevertheless, our simple model, as it may seem,
has captured the intrinsic tendency of α-ketoglutarate to
attain either of the two states. Here, we used Crabtree effect
only to illustrate this point, because of its simplicity. But,
other such feedback loops can also participate in sustaining
the glycolytic phenotype. For example, AMP-dependent
kinase, which responds to increased ATP level to suppress
mitochondrial function, can also function in similar lines as
Fig. 2 State space representation
of initial levels of α ketoglutarate
versus the rate of formation and
consumption of α ketoglutarate.
The rate of consumption of α
ketoglutarate is invariant of the
initial α ketoglutarate levels. On
the other hand, the rate of forma-
tion of α ketoglutarate varies as a
function of the initial levels of α
ketoglutarate and eventually
attains any one of the two stable
states. An initial relative α keto-
glutarate level above 0.28 would
eventually attain state S1. On the
other hand, an initial relative α
ketoglutarate level below 0.28
would eventually attain the state
S2. Thus, S1 and S2 represent the
two stable states of α ketogluta-
rate levels indicating bistability
Fig. 3 Schematic representation of the regulatory circuit that gives
rise to the bistability. α Ketoglutarate inhibits HIF1 by promoting its
degradation. HIF1 inhibits the production of α ketoglutarate by
inhibiting pyruvate entry into TCA. A decrease in α ketoglutarate
below a threshold because of stochastic reasons would increase the
HIF1 level, thus rendering a further decrease in α ketoglutarate (a).
This state corresponds to state S1 in Fig. 2. Conversely, α
ketoglutarate concentration above a threshold will ensure that the
HIF1-mediated negative feedback loop is abolished, thus increasing
the levels of α ketoglutarate (b). This state corresponds to state S2 in
Fig. 2. Double-negative feedback loops of the type shown above can
force the system to exist in either of the two stable states
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Crabtree effect (Hardie 2007). In fact, increase in HIF1
itself can act as a negative feedback loop, as mentioned
earlier (Zhang et al. 2007). Similarly, it is also likely that
loops that will force the system to attain the S1 state would
also be operational. The approach discussed here now
paves the way for a more detailed analysis of how HIF1
responds to different input signals at a systemic level.
We would like to emphasize that subsequent to the
fortuitous metabolic shift, additional mechanisms can also
come into play to stabilize the aerobic glycolysis. For
example, in breast cancer cells, the downregulation of two
isozymes of fructose 1,6 bisphosphatase (FBPase), due to
the methylation of CpG islands of the promoters of both of
the isozymes of FBPase, has been documented (Bigl et al.
2008). This could further lead to the accumulation of
fructose 1,6 bisphosphate, thus exacerbating the Crabtree
effect discussed earlier. In another example, Hexokinase 2,
one of the key enzymes thought to be responsible for
Warburg effect (see below for details), has also been shown
to be upregulated through epigenetic mechanisms (Goel et
al. 2003). Similarly, alteration in the expression of a large
array of genes through epigenetic modification has been
reported to be responsible for initiation and progression of
tumorigenesis. Thus, a fortuitous metabolic shift followed
by epigenetic modification and genetic alterations seems to
be the sequence of events that occurs in cases of sporadic
cancers.
Need for an alternate model: new perspectives
According to our model, aerobic glycolysis precedes
genetic or epigenetic changes, and this has important
implications with respect to apoptosis. Independent studies
have reported that high glycolytic rate is anti-apoptotic,
suggesting that cells destined to become cancerous a priori
escape from apoptosis. For example, the role of hexokinase
II (HXKII) and glucose metabolism in aerobic glycolysis is
highlighted by the observation that H-19 hepatoma cells
produce more lactate when glucose is used as the carbon
source as compared to galactose. Consistent with this, HXII
protein, an apoptotic suppressor, is associated with mito-
chondrial fraction only when glucose but not galactose was
used as the carbon source, indicating that apoptotic
suppression is specific to glucose metabolism (Bustamante
and Pedersen 1977; Chiara et al. 2008). In an independent
experiment, over-expression of GLUT1/HEX1 led to
significantly increased lactate with near normal or reduced
TCA metabolites, with concomitant suppression of apopto-
sis (Zhao et al. 2007). Glucose analog did not achieve the
same effect, indicating that suppression of apoptosis is
specific to glucose metabolism. It has been demonstrated
that increased glucose metabolism, observed in neuronal
and cancer cells, suppresses apoptosis by keeping the
cytochrome C, a proapoptotic factor, in its reduced state
(Vaughn and Deshmukh 2008). Further, glucose has also
been shown to suppress the apoptosis induced by p53-
dependent PUMA (Zhao et al. 2008). Therefore, we
speculate that increased aerobic glycolysis occurring a
priori can prevent the cells from entering into apoptosis,
thus obviating the need to invoke alternate mechanisms for
the suppression of apoptosis observed in cancer.
Our model suggests that the tumor population is per se
heterogenous, as there is no reason to believe that all
progenitors having aerobic glycolysis ought to give rise to
cancer. Cancer stem cells are notoriously heterogeneous in
terms of tumorigenicity in xenograft experiments, as well as
in their ability to express tumor antigens (Dick 2008; Rosen
and Jordan 2009). While the molecular basis of this
heterogeneity is not clear, it is thought to arise because of
genetic and epigenetic changes. The heterogeneity has also
been explained based on network dynamics or multiplicity
of stable genetic networks (Huang and Ingber 2007).
According to our model, the heterogeneity could as well
reflect cells trapped in different metabolic steady states and
later stabilized by stable genetic networks or genetic or
epigenetic processes. It is now becoming increasingly clear
that heterogeneity at the metabolic level is a desirable
property for tumors. For example, while some cells of
tumor population produce lactate, others consume it.
Interestingly, interfering with this metabolic symbiosis by
blocking lactate uptake suppresses tumor growth, indicating
that such a metabolic heterogeneity has a distinct advantage
to the tumor as a whole (Semenza 2008). Recently, a
similar metabolic coupling has been observed in breast
cancer (Pavlides et al. 2009), where it has been suggested
that the metabolic dependency is well-suited for the overall
growth of tumor cells. As mentioned earlier, models based
on game theory have proposed that the invasive phenotype
is more likely to succeed in a tumor population consisting
of cells with autonomous growth, glycolytic phenotype, and
invasive phenotype. Intriguingly, it has been demonstrated
that expression of frataxin, an upregulator of oxidative
phosphorylation in colon cancer lines, showed reduced
capacity for tumor formation (Schulz et al. 2008). An
explanation for the above findings is that the over-
expression of frataxin could specifically activate oxidative
phosphorylation in cells that acquired aerobic glycolysis,
thus interfering with the metabolic coupling.
Existence of heterogeneity in tumor population can also
explain the phenomenon of reversion of cancer cells to
normal cells (Kenny and Bissell 2003). For example, those
cells existing in aerobic glycolytic state that have not made
a genetic commitment to be cancerous can revert back to
the normal phenotype. It has been demonstrated that mouse
embryonic carcinoma cells, which otherwise form tumors
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upon subcutaneous injection, could develop if injected into
blastocysts (Brinster 1974). The subsequent study which
confirmed this observation suggested a non-mutational
basis for transformation to malignancy and its reversal to
normalcy (Mintz and Illmensee 1975).
Based on our model, we provide an alternate possibility
for the two-hit hypothesis of Knudson (Knudson 1971),
with respect to p53 haploinsufficiency. Theoretical analysis
shows that in general, haploinsufficiency increases tran-
scriptional noise (Cook et al. 1998). One of the roles of p53
is to increase mitochondrial oxygen uptake by activating
the transcription of SCO2, an assembly protein required for
the synthesis of cytochrome c oxidase 2 (Matoba et al.
2006). Based on this, we speculate that the p53 haploin-
sufficient cell population would show a wider cell
distribution with respect to aerobic glycolysis, since
SCO2 is a component of oxygen uptake apparatus.
Accordingly, the p53 haploinsufficient cell population is
expected to have a higher fraction of cells existing in
aerobic glycolysis because of low oxygen uptake. These
cells would proliferate rapidly, thus increasing the probability
of a mutation in the existing TP53 copy. That is, p53
haploinsufficient cells favor aerobic glycolysis because of
inherent noise. This idea is compatible with the finding that
haploinsufficiency of NF1 has been shown to increase the rate
of formation of tumors because of increased noise (Kemkemer
et al. 2002). A prediction from our hypothesis is that
metformin, a drug known to promote mitochondrial oxida-
tion by activating AMP-dependent kinase, which is an
upstream activator of p53 (Jones et al. 2005), should reduce
the incidence of tumors in individuals known to have only
one allele of TP53.
A direct prediction of our model is that an increase in the
oxidative phosphorylation would decrease or suppress the
incidence of cancer, as has been reported in literature
(Schulz et al. 2008). In contrast, an increase in the
glycolytic flux would increase the incidence of cancer.
Many independent circumstantial and experimental obser-
vations support this correlation. For example, more than
90% of ovarian cancer is due to ovulation-induced wound
repair (Godwin et al. 1993). This could be because of
increased aerobic glycolysis associated with cell prolifera-
tion which occurs during wound repair, thereby increasing
the incidence of cancer. Immortalization, the first step in
tumorigenesis, so far thought to occur because of mutations
(Carnero and Lleonart 2010), has been demonstrated to
occur upon overexpression of phosphoglycerate mutase or
phosphoglucoisomerase (Kondoh et al. 2005). As expected
from our model, this overexpression increased the glyco-
lytic flux with concomitant reduction in oxidative metab-
olism. Epidemiological data indicate that the incidence of
cancer-related mortality was higher in patients with type 2
diabetes who use insulin or sulfonylureas (Bowker et al.
2006). This could be because of increased uptake of
glucose, which exerts Crabtree effect, leading to glycolytic
phenotype. Conversely, diabetic patients consuming met-
formin show statistically significant reduction in tumor
incidence (Evans et al. 2005). This effect of metformin
could be a secondary consequence of increased mitochon-
drial oxidation of glucose, thereby preventing cells from
entering into glycolytic phenotype. In light of the above, it
is imperative that we take a closer look at the role of
metabolism in the pathophysiology of cancer.
We suggest that cells which have fortuitously acquired
aerobic glycolysis proliferate rapidly, alter the fitness
landscape and serve as precursors of cancer cells. Our
model is not only compatible with the available data, but
also satisfies three essential conditions required for the
origin and evolution of cancer cells. First, acquisition of
glycolytic phenotype would alter the fitness landscape by
producing lactate. Second, the cells that have acquired
aerobic glycolysis divide rapidly, thereby increasing the
genetic and/or epigenetic variants, which then get selected
in a dynamic fitness landscape. Third, metabolic heteroge-
neity of tumor cell population is an intrinsic feature of our
model, and appears to play a significant role in the
pathophysiology of cancer. Thus, the basic tenet of our
model that the genetic and/or epigenetic changes can occur
subsequent to the cells acquiring aerobic glycolysis unifies
our current understanding of the origin and progression of
cancer. Further, it places the concept that the “origin and
progression of cancer is analogous to Darwinian evolution”
on firmer ground, with the exception that the initial event
can also be nongenetic.
Conclusions
While the importance of Warburg effect in tumor metabo-
lism is now widely accepted, it is still tacitly believed that it
occurs subsequent to genetic or epigenetic changes during
tumorigenesis. On the other hand, in spite of intense efforts
and a wealth of data, we continue to grapple with the idea
that genetic and epigenetic changes are the root causes of
cancer. This dichotomy has only widened the gap between
the genetic and metabolic basis of cancer. Our hypothesis
that because of noise, a stable glycolytic phenotype can be
manifested and propagated during cell division in normal
cells, independent of genetic or epigenetic event, provides a
conceptually new avenue that would radically alter the way
we think about cancer. We point out that metabolomes and
genomes are intricately intertwined at the functional level,
and attempts to subjugate metabolism as only a secondary
consequence of genetic or epigenetic changes is unlikely to
bear fruits. It appears that the major target of evolutionary
force during evolution of eucaryotes are the regulatory
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circuits that link metabolism, which provides the cellular
fabric plus fuel with that of the genome, which encapsulates
the genetic program. That enzymes involved in glycolysis and
TCA are moonlighting proteins (Sriram et al. 2005; Gancedo
and Flores 2008) with diverse roles, such as transcriptional
activation, suppression of apoptosis etc., supports the above
conjecture. In light of this, it is imperative to consider
metabolism as a prime player in the overall orchestration of
many aberrant biological processes, including tumorigenesis.
Therefore, we suggest that Warburg effect be considered
more as a causative agent than as a metabolic shift required
only for tumor progression.
Attempts to elucidate the role of cytoplasmic factors in
dictating the phenotypic outcome invariably takes us back
to the fundamental observations made by Waddington in
1950s. He coined the term “epigenotype”, specifically to
highlight the role of cytoplasmic factors in the eventual
translation of the genotype to the phenotype. The molecular
basis of this concept is only now beginning to be
understood in greater detail. The above concept was
developed in an attempt to describe the various develop-
mental fates originating from a given genotype. To explain
this, he used the metaphor “epigenetic landscape” to refer
to the possible phenotypic states that a cell can potentially
attain (reviewed in Gilbert 2000). One may consider a
cancerous state as one of the aberrant developmental
options available to a normal cell (Kauffman 1971).
However, because of canalization, or the robustness of
developmental pathways, cells normally do not take this
aberrant route; that is, invariably the cells are canalized to
follow the destined developmental trajectory under normal
conditions, but if the cellular conditions are altered beyond
a threshold, they may attain an aberrant phenotypic state.
Thus, based on the fundamental ideas of Warburg and
Waddington, as well as our current understanding, we have
synthesized a novel concept which has far-reaching
ramifications, as far as cancer biology is concerned.
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